Present and future of influenza prevention in pediatrics

Expert Opinion on Biological Therapy

Volumn 11, Issue 5, 2011, Pages 641-653

  Principi, Nicola ^a   Esposito, Susanna ^a   Marchisio, Paola ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Adjuvants; children; influenza; influenza vaccines; prevention; vaccination

Indexed keywords

AS03 VACCINE; HEMAGGLUTININ; INACTIVATED VACCINE; INFLUENZA VACCINE; LIVE COLD ADAPTED INTRANASAL VACCINE; MIFAMURTIDE; PLACEBO; SIALIDASE; TRIVALENT INACTIVATED INFLUENZA VACCINE; UNCLASSIFIED DRUG; VIROSOMAL ADJUVANTED INACTIVATED VACCINE; VIROSOME ADJUVANTED SEASONAL VACCINE; VIROSOME VACCINE;

BRONCHOSPASM; DIARRHEA; DRUG DELIVERY SYSTEM; DRUG FEVER; EATING HABIT; ERYTHEMA; HUMAN; IMMUNOGENICITY; INFECTION PREVENTION; INFLUENZA; INFLUENZA VACCINATION; IRRITABILITY; NONHUMAN; PAIN; PEDIATRICS; REVIEW; RHINITIS; SIDE EFFECT; SOMNOLENCE; SWELLING; VOMITING;

ANTIVIRAL AGENTS; CHILD; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; PEDIATRICS;

EID: 79953893773     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2011.562495     Document Type: Review

References (90)

1. Mullooly JP, Barker WH. Impact of type A influenza on children: a retrospective study. Am J Public Health 1982;72:1008-16
2. Glezen WP, Decker M, Perrotta DM. Survey of underlying conditions of persons hospitalized with acute respiratory disease during influenza epidemics in Houston, 1978-1981. Am Rev Respir Dis 1987;136:550-5 (Pubitemid 18007351)
3. Simonsen L, Fukuda K, Schonberger LB, et al. The impact of influenza epidemics on hospitalizations. J Infect Dis 2000;181:831-7 (Pubitemid 30194462)
4. Izurieta HS, Thompson WW, Kramarz P, et al. Influenza and the rates of hospitalization for respiratory disease among infants and young children. N Engl J Med 2000;342:232-9 (Pubitemid 30058954)
5. Iwane MK, Edwards KM, Szilagyi PG, et al. Population-based surveillance for hospitalizations associated with respiratory syncytial virus, influenza virus, and parainfluenza viruses among young children. Pediatrics 2004;113:1758-64 (Pubitemid 38697988)
6. Ampofo K, Gesteland PH, Bender J, et al. Epidemiology, complications, and cost of hospitalization in children with laboratory-confirmed influenza infection. Pediatrics 2006;118:2409-17 (Pubitemid 46397581)
7. Coffin SE, Zaoutis TE, Rosenquist AB, et al. Incidence, complications, and risk factors for prolonged stay in children hospitalized with community-acquired influenza. Pediatrics 2007;119:740-8 (Pubitemid 46556673)
8. Chiu SS, Chan K-H, Chen H, et al. Virologically confirmed population-based burden of hospitalization caused by influenza A and B among children in Hong Kong. Clin Infect Dis 2009;49:1016-21
9. Principi N, Esposito S, Marchisio P, et al. Socioeconomic impact of influenza on healthy children and their families. Pediatr Infect Dis J 2003;22(Suppl 10):S207-10 (Pubitemid 37288598)
10. Bhat N, Wright JG, Broder KR, et al. Influenza-associated deaths among children in the United States, 2003-2004. N Engl J Med 2005;353:2559-67 (Pubitemid 41785893)
11. Louie JK, Schechter R, Honarmand S, et al. Severe pediatric influenza in California, 2003-2005: implications for immunization recommendations. Pediatrics 2006;117:e610-18 (Pubitemid 46071465)
12. Smith SM, Gums JG. Antivirals for influenza: strategies for use in pediatrics. Paediatr Drugs 2010;12:285-99
13. Esposito S, Molteni CG, Daleno C, et al. Clinical importance and impact on the households of oseltamivir-resistant seasonal A/H1N1 influenza virus in healthy children in Italy. Virol J 2010;7:202
14. Esposito S, Molteni CG, Colombo C, et al. Oseltamivir-induced resistant pandemic A/H1N1 influenza virus in a child with cystic fibrosis and Pseudomonas aeruginosa infection. J Clin Virol 2010;48:62-5
15. Shun-Shin M, Thompson M, Heneghan C, et al. Neuraminidase inhibitors for treatment and prophylaxis of influenza in children: systematic review and meta-analysis of randomized controlled trials. BMJ 2009;339:b3172
16. Edwards KM. The burden of influenza in children: time for prevention. Clin Infect Dis 2009;49:1022-4
17. Fiore AE, Uyeki TM, Broder K, et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep 2010;59:1-62
18. Esposito S, Principi N. The rational use of influenza vaccines in healthy children and children with underlying conditions. Curr Opin Infect Dis 2009;22:244-9
19. Heinonen S, Silvennoinen H, Lehtinen P, et al. Effectiveness of inactivated influenza vaccine in children aged 9 months to 3 years: an observational cohort study. Lancet Infect Dis 2011;11:23-9
20. Austria: Impfplan 2010 Osterreich: korrigiert. Available from: http://www.bmgfj.gv.at/cms/home/attachments/2/1/2/CH1015/CMS1287855495948/ the-austrian-health-care-system-2010-e1.pdf
21. Jefferson T, Rivetti A, Harnden A, et al. Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev 2008;2:CD004879
22. Mitchell DK, Ruben FL, Gravenstein S. Immunogenicity and safety of inactivated influenza virus vaccine in young children in 2003-2004. Pediatr Infect Dis J 2005;24:925-7 (Pubitemid 41475932)
23. Ansaldi F, Canepa P, Parodi V, et al. Adjuvanted seasonal influenza vaccines and perpetual viral metamorphosis: the importance of cross-protection. Vaccine 2009;27:3345-8
24. Zeman AM, Holmes TH, Stamatis S, et al. Humoral and cellular immune response in children given annual immunization with trivalent inactivated influenza vaccine. Pediatr Infect Dis J 2007;26:107-15 (Pubitemid 46183359)
25. Belshe RB, Edwards KM, Vesikari T, et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007;356:685-96
26. Oster G, Weycker D, Edelsberg J, et al. Benefits and risks of live attenuated influenza vaccine in young children. Am J Manag Care 2010;16:e235-44
27. Marchisio P, Cavagna R, Maspes B, et al. Efficacy of intranasal virosomal influenza vaccine in the prevention of recurrent acute otitis media in children. Clin Infect Dis 2002;35:168-74 (Pubitemid 34753902)
28. Mutsch M, Zhou W, Rhodes P, et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N Engl J Med 2004;350:896-903 (Pubitemid 38252537)
29. Vesikari T, Karvonen A, Smith HM, et al. Safety and tolerability of cold-adapted influenza vaccine, trivalent, in infants younger than 6 months of age. Pediatrics 2008;121:e568-73
30. Ashkenazi S, Vertruyen A, Aristegui J, et al. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatr Infect Dis J 2006;25:870-9 (Pubitemid 44510578)
31. Yang CF, Belshe RB, Kemble G, et al. Genetic sequence analysis of influenza viruses and illness severity in ill children previously vaccinated with live attenuated or inactivated influenza vaccine. Vaccine 2010;28:5128-34
32. Nichol KL, Mendelman PM, Mallon KP, et al. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. JAMA 1999;282:137-44 (Pubitemid 29323803)
33. De Villiers PJ, Steele AD, Hiemstra LA, et al. Efficacy and safety of a live attenuated influenza vaccine in adults 60 years of age and older. Vaccine 2009;28:228-34
34. Eick AA, Wang Z, Hughes H, et al. Comparison of the trivalent live attenuated vs. inactivated influenza vaccines among U.S. military service members. Vaccine 2009;27:3568-75
35. Rhorer J, Ambrose CS, Dickinson S, et al. Efficacy of live attenuated influenza vaccine in children: a meta-analysis of nine randomized clinical trials. Vaccine 2009;27:1101-10
36. Izurieta HS, Haber P, Wise RP, et al. Adverse events reported following live, cold-adapted, intranasal influenza vaccine. JAMA 2005;294:2720-5 (Pubitemid 41770101)
37. Bis Kersten C, Hirschberg H. Antigen delivery system. Expert Rev Vaccines 2004;3:453-62
38. Falsey AR New emerging technologies and the intradermal route: the novel way to immunize against influenza. Vaccine 2010;28(Suppl 4):D24-32
39. Pearton M, Kang SM, Song JM, et al. Changes in human Langerhans cells following intradermal injection of influenza virus-like particle vaccines. PLoS One 2010;5:e12410
40. Saville M, Marsh G, Hoffenbach A. Improving seasonal and pandemic influenza vaccines. Influenza Other Respir Viruses 2008;2:229-35
41. Sullivan SP, Koutsonanos DG, Del Pilar Martin M, et al. Dissolving polymer microneedle patches for influenza vaccination. Nat Med 2010;16:915-20
42. Kim YC, Quan FS, Yoo DG, et al. Enhanced memory responses to seasonal H1N1 influenza vaccination of the skin with the use of vaccine-coated microneedles. J Infect Dis 2010;201:190-8
43. Vankerckhoven V, Van Damme P. Clinical studies assessing immunogenicity and safety of intradermally administered influenza vaccines. Expert Opin Drug Deliv 2010;7:1109-25
44. Sugimura T, Ito Y, Tananari Y, et al. Improved antibody responses in infants less than 1 year old using intradermal influenza vaccination. Vaccine 2008;26:2700-5
45. Chiu SS, Chan KH, Tu W, et al. Immunogenicity and safety of intradermal versus intramuscular route of influenza immunization in infants less than 6 months of age: a randomized controlled trial. Vaccine 2009;27:4834-9
46. Cools HJM, Gussekloo J, Remmerswaal JEM, et al. Benefits of increasing the dose of influenza vaccine in residents of long-term facilities: a randomized placebo-controlled trial. J Med Virol 2009;81:904-14
47. Keitel WA, Atmar RL, Cate TR, et al. Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons. Arch Inter Med 2006;166:1121-7 (Pubitemid 43765184)
48. Couch Rb, Winokur P, Brady R, et al. Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects. Vaccine 2007;25:7656-63 (Pubitemid 47554468)
49. Palache AM, Beyer WEP, Sprenger MJW, et al. Antibody response after influenza immunization with various vaccines doses: a double-blind, placebo-controlled, multi-centre, dose-response study in elderly nursing-home residents and young volunteers. Vaccine 1993;11:3-7
50. Palache AM, Beyer WEP, Osterhaus ADME. Influenza vaccine dosages. Vaccine 2008;26:2305-6
51. Esposito S, Marchisio P, Ansaldi F, et al. A randomized clinical trial assessing immunogenicity and safety of a double dose of virosomal-adjuvanted influenza vaccine administered to unprimed children aged 6-35 months. Vaccine 2010;28:6137-44
52. Bresson JL, Perronne C, Launay O, et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 2006;367:1657-64 (Pubitemid 43744370)
53. Bernstein DI, Edwards KM, Dekker CL, et al. Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. J Infect Dis 2008;197:667-75 (Pubitemid 351364465)
54. Petrovsky N, Aguilar JC. Vaccine adjuvants: current state and future trends. Immunol Cell Biol 2004;82:488-96 (Pubitemid 39421058)
55. Calcagnile S, Zuccotti GV. The virosomal adjuvanted influenza vaccine. Expert Opin Biol Ther 2010;10:191-200
56. Arkema A, Huckriede A, Schoen P, et al. Induction of cytotoxic activity by fusion active peptide-containing virosome. Vaccine 2000;18:1327-33 (Pubitemid 30017844)
57. Huckriede A, Bungener I, Stegman T, et al. The virosome concept for influenza vaccines. Vaccine 2005;23:S33-6
58. Salleras L, Dominguez A, Pumarola T, et al. Effectiveness of virosomal subunit influenza vaccine in preventing influenza-related illness and its social and economic consequences in children aged 3-14 years: a prospective cohort study. Vaccine 2006;24:6638-42 (Pubitemid 46107153)
59. Marchisio P, Esposito S, Bianchini S, et al. Efficacy of injectable trivalent virosomal-adjuvanted inactivated influenza vaccine in preventing acute otitis media in children with recurrent complicated or noncomplicated acute otitis media. Pediatr Infect Dis J 2009;28:855-9
60. Esposito S, Marchisio P, Cavagna R, et al. Effectiveness of influenza vaccination of children with recurrent respiratory tract infections in reducing respiratory-related morbidity within households. Vaccine 2003;21:3162-8 (Pubitemid 36694558)
61. Zuccotti G, Amendola A, Vigano A, et al. Long-term immunogenicity of a virosomal subunit inactivated influenza vaccine in children with asthma. Vaccine 2007;25:6692-8 (Pubitemid 47332732)
62. Zuccotti GV, Scaramuzza A, Riboni S, et al. Long-lasting immunogenicity of a virosomal vaccine in older children and young adults with type I diabetes mellitus. Vaccine 2009;27:5357-62
63. Tanzi E, Esposito S, Bojanin J, et al. Immunogenicity and effect of a virosomal influenza vaccine on viral replication and T-cell activation in HIV-infected children receiving highly active antiretroviral therapy. J Med Virol 2006;78:440-59
64. Vigano A, Zuccotti GV, Pacei M, et al. Humoral and cellular response to influenza vaccine in HIV-infected children with full viroimmunologic response to antiretroviral therapy. J Acquir Immune Defic Syndr 2008;48:289-96
65. Kanra G, Marchisio P, Feiterna-Sperling C, et al. Comparison of immunogenicity and tolerability of a virosome-adjuvanted and a split influenza vaccine in children. Pediatr Infect Dis J 2004;23:300-6 (Pubitemid 38508880)
66. Kusteiner O, Moser C, Lazar H, Durrer P. InflexalV-the influenza vaccine with the lowest albumin content. Vaccine 2006;24:6632-65
67. Esposito S, Gasparini C, Martelli A, et al. Safe administration of an inactivated virosomal adjuvanted influenza vaccine in asthmatic children with egg allergy. Vaccine 2008;26:4664-8
68. O'Hagan DT, Wack A, Podda A. MF59 is a safe and potent vaccine adjuvant for flu vaccines in humans: what did we learn during its development? Clin Pharmacol Ther 2007;82:740-4 (Pubitemid 350114825)
69. O'Hagan DT. MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection. Expert Rev Vaccines 2007;6:699-710 (Pubitemid 47607847)
70. Durando P, Icardi G, Ansaldi F. MF59-adjuvanted vaccine: a safe and useful tool to enhance and broaden protection against seasonal influenza viruses in subjects at risk. Expert Opin Biol Ther 2010;10:639-51
71. Vesikari T, Pellegrini M, Karvonen A, et al. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant. Pediatr Infect Dis J 2009;28:563-571
72. Vesikari T, Groth N, Karvonen A, et al. MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination. Vaccine 2009;27:6291-5
73. Esposito S, Pugni L, Daleno C, et al. Monovalent pandemic influenza A/H1N1 MF59-adjuvanted vaccine in pre-and full-term children aged 6-23 months. Pediatrics 2011; In press
74. Vesikari T, Karvonen A, Tilman S, et al. Immunogenicity and safety of MF59-adjuvanted H5N1 influenza vaccine from infancy to adolescence. Pediatrics 2010;126:e762-70
75. Black S, Della Cioppa G, Malfroot A, et al. Safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents: an integrated analysis. Vaccine 2010;28:7331-6
76. Lippi G, Targher G, Franchini M. Vaccination, squalene and anti-squalene antibodies. Facts or fiction? Eur J Intern Med 2010;21:70-3
77. Carmona A, Omenaca F, Tejedor JC, et al. Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6-35 months. Vaccine 2010;28:5837-44
78. Schwarz TF, Horacek T, Knuf M, et al. Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults. Vaccine 2009;27:6284-90
79. Roman F, Vaman T, Gerlach B, et al. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial. Vaccine 2010;28:1740-5
80. Diez-Domingo J, Garces-Sanchez M, Baldo JM, et al. Immunogenicity and safety ofH5N1 A/Vietnam/1194/2004 (Clade 1) AS03-adjuvanted prepandemic candidate influenza vaccines in children aged 3 to 9 years: a Phase II, randomized, open, controlled study. Pediatr Infect Dis J 2010;29:e35-46
81. Waddington CS, Walker WT, Oeser C, et al. Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study. BMJ 2010;340:c2649
82. Stropkovska A, Janulikova J, Vareckova E. Trends in development of the influenza vaccine with broader cross-protection. Acta Virol 2010;54:7-19
83. Genzel Y, Reichl U. Continuous cell lines as a production system for influenza vaccines. Expert Rev Vaccines 2009;8:1681-92
84. Barrett PN, Portsmouth D, Ehrlich HJ. Developing cell culture-derived pandemic vaccines. Curr Opin Mol Ther 2010;12:21-30
85. Hussain AI, Cordeiro M, Sevilla E, Liu J. Comparison of egg and high yielding MDCK cell-derived live attenuated influenza virus for commercial production of trivalent influenza vaccine: in vitro cell susceptibility and influenza virus replication kinetics in permissive and semi-permissive cells. Vaccine 2010;28:3848-55
86. Smith LR, Wloch MK, Ye M, et al. Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin. Vaccine 2010;28:2565-72
87. Tompkins SM, Zhao ZS, Lo CY, et al. Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Emerg Infect Dis 2007;13:426-35 (Pubitemid 46348126)
88. Prabhu N, Prabakaran M, Ho HT, et al. Monoclonal antibodies against the fusion peptide of hemagglutinin protect mice from lethal influenza A virus H5N1 infection. J Virol 2009;83:2553-62
89. Zaman K, Roy E, Arifeen SE, et al. Effectiveness of maternal influenza immunization in mothers and infants. N Engl J Med 2008;359:1555-64
90. Pownall M. Pregnant women to be included in target group for flu vaccination. BMJ 2010;341:c5432